Download - 01 Biopharmaceutics
![Page 1: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/1.jpg)
Biopharmaceutics and Pharmacokinetics
Ivan N. Tanodra, MD, RPh
![Page 2: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/2.jpg)
Bio=Pharmaceutics
Lifegeneral area of study general area of study concerned with the concerned with the formulation, formulation, manufacture, stability manufacture, stability and effectiveness of and effectiveness of pharmaceutical dosage pharmaceutical dosage formsforms
![Page 3: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/3.jpg)
Biopharmaceutics
• study of the factors influencing the bioavailability of a drug in man and animals and the use of this information to optimize pharmacological or therapeutic activity of drug products in clinical application
![Page 4: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/4.jpg)
Biopharmaceutics
• Interrelationship of the physicochemical properties of the drug, the dosage form in which the drug is given, and the route of administration on the rate and extent of drug absorption
![Page 5: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/5.jpg)
Biopharmaceutics
• Study of the relationship of the physicochemical properties and in vitro behavior of the drug & drug product on the delivery of the drug to the body under normal or pathologic conditions
![Page 6: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/6.jpg)
•PHARMACOKINETICS – a process of how the body deals with the drug, “what your body does to your drug”
•PHARMACODYNAMICS – a process of how your drug deals with the body, “what your drug does to your body”
![Page 7: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/7.jpg)
Pharmacokinetics
• Deals with the changes of drug concentration in a drug product inside the human or animal body following administration
![Page 8: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/8.jpg)
Pharmacokinetics
• Involves the kinetics of drug absorption, distribution, metabolism and elimination
![Page 9: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/9.jpg)
Pharmacodynamics
• Relationship between the drug concentration at the site of action (receptor) and pharmacologic response
![Page 10: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/10.jpg)
Drug Product
• Finished dosage form that contains an active drug ingredient generally, but not necessarily, in association with inactive ingredient (vehicle)
• Formulation or matrix in which the drug is contained
• Term may also include a dosage form that does not contain an active ingredient intended to be used = placebo
![Page 11: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/11.jpg)
Physicochemical properties of drug product
Pharmacologic/clinical effect
![Page 12: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/12.jpg)
Rationale
• Apply biopharmaceutic principles in developing a rational design of a drug product which would enhance the delivery of active drug and provide optimal therapeutic efficacy of the drug in the patient
![Page 13: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/13.jpg)
AIM:
To deliver the right amount of drug that is EFFECTIVEand SAFE at the right place (site of action) and at the right time (oral, SL or IV/ fast or slow-release)
![Page 14: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/14.jpg)
• Mometasone cream AND Mometasone (Nasonex) nasal spray
• Methylprednisolone tablet AND Fluticasone spray• Salbutamol nebules, Salbutamol MDI and
Salbutamol syrup• Nitroglycerin patch AND Nitroglycerin spray• Lactacyd facial wash AND Lactacyd feminine wash• Atropine eyedrops AND Atropine ampule• Lidocaine spray, Epinephrine ampule and
Lidocaine:Epinephrine carpule
![Page 15: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/15.jpg)
Let us now focus on drugs intended for systemic use….
![Page 16: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/16.jpg)
Let’s discuss the disposition of a drug
DOSAGE FORMROUTE OF ADMINISTRATION
![Page 17: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/17.jpg)
Bioavailability of the drug (active ingredient) is the primary concern of biopharmaceutics- Remember you AIM
![Page 18: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/18.jpg)
How do you measure the bioavailability of a drug?
1. Blood = plasma level concentration2. Urine3. Feces – reflect a drug that has not been
absorbed after an oral dose or a drug that has been biliary secreted after systemic absorption
4. Clinical outcome/Pharmacologic effect/pharmacodynamic effect
Which is the most direct measurement?
![Page 19: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/19.jpg)
Plasma Level – Time Curve
Time (mins.)
Plasma level (mg/mL)
![Page 20: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/20.jpg)
Identify….
• Peak plasma level (cmax)– max drug concentration related to the dose & the rate constants for absorption & elimination of the drug
• AUC (Area Under the Curve)- related to the amount of drug absorbed systemically
• Time of peak plasma level (tmax)– time of max drug conc. in plasma roughly proportional to the average rate of drug absorption
![Page 21: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/21.jpg)
Determine the route of administration
• IV• Oral
![Page 22: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/22.jpg)
Higher plasma level concentration = ___________? bioavailability
![Page 23: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/23.jpg)
Establish
• Minimum effective concentration (MEC)• Minimum toxic concentration (MTC)
![Page 24: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/24.jpg)
You will be able to determine….
•Onset time of action•Duration of action• Intensity of drug actio
•--Through the plasma level time curve
![Page 25: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/25.jpg)
Most of the time……..
Plasma level concentration of a drug = concentration of drug at the receptor sites = intensity of a pharmacologic effect
![Page 26: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/26.jpg)
Is measuring plasma concentrations of a drug enough
to determine its therapeutic efficacy?
![Page 27: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/27.jpg)
Pharmacodynamic Response
•Digoxin = ECG tracings•Warfarin = Prothrombin time• Insulin = Blood glucose levels•Simvastatin = Blood cholesterol levels•Nifedipine (anti-hypertensive) =
___________________•Paracetamol = ___________________
![Page 28: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/28.jpg)
Plasma drug concentrations do not accurately predict pharmacodynamic response
Action of warfarin is dependent on the clotting factors II, VII, IX & X
![Page 29: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/29.jpg)
Having the same trend of plasma level concentration of Warfarin…..
• Will the intensity of the activity of Warfarin in a hemophiliac be the same with a normal person?
![Page 30: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/30.jpg)
IQ
A 64 year-old male, diabetic patient with a poor creatinine clearance is being given Gentamycin 80mg (aminoglyocside) IV once daily as a treatment for sepsis. Which is important:
a.Blood culture and sensitivity to determine his response to treatment
b.Plasma level concentration to determine the blood level of the drug
c.A and B
Why?
![Page 31: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/31.jpg)
Pharmacokinetic Models
• Drugs are in a dynamic state within the body
• It is a hypothesis conceived using mathematical terms
• Describe drug concentrations in the body as a function of unit time
![Page 32: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/32.jpg)
Pharmacokinetic Models
Concentration of drug in the tank would be governed by two parameters which are CONSTANT:
1.Fluid volume of the tank2.Elimination of drug per unit of time
![Page 33: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/33.jpg)
Let us correlate the LADMER System with Pharmacokinetic Models
![Page 34: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/34.jpg)
Pharmacokinetic Models
If a known set of drug concentrations in the tank were determined at various intervals à volume of fluid in the tank & rate of drug elimination would be established
![Page 35: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/35.jpg)
Pharmacokinetic Models
• A compartment is a tank containing a volume of fluid
• In the human body, a fraction of drug is continually eliminated as a function of time
![Page 36: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/36.jpg)
Pharmacokinetic Models
•Concentration of drug in the tank (compartment) after a given dose (Ab) is governed by two parameters:1. Fluid volume of the tank (Vd)2. Elimination of drug per unit of time (kel, CL)
à this could be established by knowing a set of drug concentrations in the tank (Cp) at various time intervals
![Page 37: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/37.jpg)
Pharmacokinetic Models
•The number of parameters needed to describe the model depends on:1. Complexity of the process (ADME)2. route of drug administration
![Page 38: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/38.jpg)
Uses of Pharmacokinetic Models
• Predict plasma, tissue and urine drug levels with any dosage regimen
• Calculate the optimum dosage regimen for each patient individually
• Estimate possible accumulation of drug and/or metabolites
• Correlate drug concentrations with pharmacologic or toxicologic activity
![Page 39: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/39.jpg)
Uses of Pharmacokinetic Models
• Evaluate differences in the rate or extent of availability between formulations (bioequivalence)
• Describe how changes in physiology or disease affect the absorption, distribution and elimination of the drug
• Explain drug interactions
![Page 40: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/40.jpg)
Pharmacokinetic Models
A.Compartment Model (Mammillary Model) B.Physiologic Pharmacokinetic Model (Flow
Model)
![Page 41: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/41.jpg)
Compartment (Mammillary) Model
• One or more peripheral compartment connected to a central compartment like satellites
• DRUG IN THE BODY = CENTRAL COMPARTMENT + TISSUE COMPARTMENT
![Page 42: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/42.jpg)
Compartment (Mammillary) Model
Compartment is not a real physiologic or anatomic region
Used when there is little information known about the tissues
ASSUMPTION: Compartment à group of tissues that have a similar blood flow and drug affinity
Within each compartment, drug is uniformly distributed
OPEN – drugs move in & out of the compartment (dynamic)
![Page 43: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/43.jpg)
Compartment (Mammillary) Model
ASSUMPTION:•Drug has an equal probability of leaving the compartment
![Page 44: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/44.jpg)
Compartment Models
• Rate constants (ka & ke) represents the overall rate processes of drug entry into and exit from the compartments
![Page 45: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/45.jpg)
Compartment Model
FUNCTIONS:•Enables the pharmacokineticist to write
different equations to drug concentration changes inside each compartment
•Visual representation of rate processes•Shows how many pharmacokinetic
constants are necessary to describe the process adequately
![Page 46: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/46.jpg)
Compartment Models
•Open-one compartment model•Open-two compartment model
•Compartment model for IV and oral
![Page 47: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/47.jpg)
Compartment Model
• Can a drug concentration data be obtained directly from each compartment???
• In open two compartment à data in the peripheral compartment cannot be obtained à tissues are not easily sampled & may not contain homogenous concentration of the drug à only estimated mathematically (from amount of drug absorbed & eliminated per unit time)
![Page 48: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/48.jpg)
Compartment Model
DISADVANTAGES:•NOT REALISTIC because everything is
based on presumption and mathematical concept•à Cannot be extrapolated to humans
![Page 49: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/49.jpg)
Physiologic Pharmacokinetic Model
• Blood flow or perfusion model• Based on known anatomic and physiologic data
à MORE REALISTIC• Actual tissue volume is used• Experimentally determined in ANIMALS à
extrapolated to humans• No data fitting required• On model à if there’s no perfusion, organ is
excluded (e.g. brain)
![Page 50: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/50.jpg)
Construct the model….
• IV injection, Venous blood, Arterial blood, Heart, Muscle, Slowly equilibrating tissue (SET), Rapidly equilibrating tissue (RET), Kidney, Liver, ke, km, Perfusion (Q) Qh, Qm, Qs, Qr, Qk, Ql, Urine
![Page 51: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/51.jpg)
Physiologic Pharmacokinetic Model
• DISADVANTAGE: 1.Data can be experimentally difficult to
obtain2.Data can be affected by pathophysiologic
conditions
![Page 52: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/52.jpg)
Factors Affecting Design of a Drug Product
DRUG•Dosage form•Dose (mg/kg)•Physicochemical
properties•Route of administration
BODY•Physiologic factors
(e.g. age, body mass)•Pathologic factors (e.g.
liver and renal disease)
![Page 53: 01 Biopharmaceutics](https://reader034.vdocuments.us/reader034/viewer/2022042602/55cf99ba550346d0339ee0f5/html5/thumbnails/53.jpg)
Application of Biopharmaceutics
• Generic equivalency• Drug availability• Therapeutic efficacy• Drug substitution